Unlocking New Insights About the Breast Cancer Index Test
Unlocking New Insights About the Breast Cancer Index Test
New Evidence from 2025 SABCS and Beyond Reinforcing:
- The Breast Cancer Index Test remains the leading test for extended endocrine therapy decision-making: Exclusive Guideline Recognition. Extensively Validated. Proven Clinical Impact.
- Endocrine therapy adherence remains a challenge, with a significant percentage of women discontinuing treatment prior to the 5-year mark.
- New data supporting expanded applications of the Breast Cancer index Test will support earlier personalized decisions to help women avoid unnecessary side effect or gain commitment to their treatment plan from the start (coming soon).*
*Not currently available to order
The features and results of the Breast Cancer Index Test, to the extent they differ from the information found on the breastcancerindex.com website, including, but not limited to, the features concerning adjuvant endocrine therapy and ovarian function suppression: (i) are not currently available for clinical use; (ii) will be made available only after all required internal validations and regulatory requirements have been met; and (iii) is being provided herein for informational purposes only, and shall not be deemed to be an offer of availability.